LOS ANGELES, Jan. 31, 2011 /PRNewswire/ — ImaginAb, Inc. and
Eurogentec S.A. announce a development collaboration to establish a
novel system for producing engineered antibody fragments. The two
companies will produce ImaginAb’s optimized antibody fragments with
Eurogentec’s high-performance Pichia pastoris expression
system. Leveraging Eurogentec’s expertise in cGMP manufacturing of
recombinant proteins, the collaboration will accelerate the
development of ImaginAb’s rich pipeline of targeted molecular
imaging agents for the diagnosis and treatment management of cancer
and autoimmune diseases.
“With our rapidly expanding pharma client base worldwide,
ImaginAb is leveraging multiple manufacturing technologies to
increase our capacity for fast, reliable protein production,” said
Dr. Christian Behrenbruch, CEO of ImaginAb. “Eurogentec’s
Pichia technology has the potential to enable us to take a
fresh look at how we do extremely rapid and cost-effective
translation into humans with our antibody fragment technology.”
Dr. Philippe Cronet, CSO of Eurogentec commented, “We are very
committed to exploring new manufacturing strategies for ImaginAb’s
unique products. Our technology platform is well suited to a
variety of recombinant proteins including the important class of
antibody fragment proteins such as those under development by
ImaginAb”.
About ImaginAb
Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and
Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company
specializing in the development of engineered antibody fragments
for diagnostic imaging and novel therapeutic applications. The
company has a significant pipeline of clinical products in
development oriented towards unmet needs in cancer and immunology.
ImaginAb is also developing a range of pre-clinical (animal
imaging) reagents for use with microPET, microSPECT and optical
imaging systems, and partners on a selective basis with bi
‘/>”/>